160 related articles for article (PubMed ID: 30553548)
1. Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
Ono A; Isaka M; Serizawa M; Omae K; Kojima H; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Urakami K; Nagashima T; Sugino T; Kusuhara M; Takahashi T; Yamaguchi K; Ohde Y
Lung Cancer; 2019 Feb; 128():152-157. PubMed ID: 30553548
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
3. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
4. Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.
Devarakonda S; Rotolo F; Tsao MS; Lanc I; Brambilla E; Masood A; Olaussen KA; Fulton R; Sakashita S; McLeer-Florin A; Ding K; Le Teuff G; Shepherd FA; Pignon JP; Graziano SL; Kratzke R; Soria JC; Seymour L; Govindan R; Michiels S
J Clin Oncol; 2018 Oct; 36(30):2995-3006. PubMed ID: 30106638
[TBL] [Abstract][Full Text] [Related]
5. Extracapsular extension is a powerful prognostic factor in stage IIA-IIIA non-small cell lung cancer patients with completely resection.
Liu W; Shao Y; Guan B; Hao J; Cheng X; Ji K; Wang K
Int J Clin Exp Pathol; 2015; 8(9):11268-77. PubMed ID: 26617851
[TBL] [Abstract][Full Text] [Related]
6. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
7. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J; Chen N; Qi J; Zhou B; Qiu X
J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
9. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
10. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data.
Xu S; Wang Y; Ren F; Li X; Ren D; Dong M; Chen G; Song Z; Chen J
Cancer Med; 2020 Oct; 9(20):7686-7694. PubMed ID: 32857918
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
[TBL] [Abstract][Full Text] [Related]
12. Signaling pathway-based identification of extensive prognostic gene signatures for lung adenocarcinoma.
Wan YW; Beer DG; Guo NL
Lung Cancer; 2012 Apr; 76(1):98-105. PubMed ID: 22047960
[TBL] [Abstract][Full Text] [Related]
13. High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.
Ludovini V; Bellezza G; Pistola L; Bianconi F; Di Carlo L; Sidoni A; Semeraro A; Del Sordo R; Tofanetti FR; Mameli MG; Daddi G; Cavaliere A; Tonato M; Crinò L
Ann Oncol; 2009 May; 20(5):842-9. PubMed ID: 19153117
[TBL] [Abstract][Full Text] [Related]
14. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
[TBL] [Abstract][Full Text] [Related]
15. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
[TBL] [Abstract][Full Text] [Related]
16. Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction/adjuvant chemotherapy.
Saisho S; Yasuda K; Maeda A; Yukawa T; Okita R; Hirami Y; Shimizu K; Nakata M
Interact Cardiovasc Thorac Surg; 2013 Feb; 16(2):166-72. PubMed ID: 23143203
[TBL] [Abstract][Full Text] [Related]
17. Overall survival of driver mutation-negative non-small cell lung cancer patients with COPD under chemotherapy compared to non-COPD non-small cell lung cancer patients.
Lim JU; Yeo CD; Rhee CK; Kim YH; Park CK; Kim JS; Kim JW; Kim SJ; Yoon HK; Lee SH
Int J Chron Obstruct Pulmon Dis; 2018; 13():2139-2146. PubMed ID: 30034229
[TBL] [Abstract][Full Text] [Related]
18. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
19. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With
Tada H; Mitsudomi T; Misumi T; Sugio K; Tsuboi M; Okamoto I; Iwamoto Y; Sakakura N; Sugawara S; Atagi S; Takahashi T; Hayashi H; Okada M; Inokawa H; Yoshioka H; Takahashi K; Higashiyama M; Yoshino I; Nakagawa K;
J Clin Oncol; 2022 Jan; 40(3):231-241. PubMed ID: 34726958
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of nuclear factor of activated T-cells 5 expression in non-small cell lung cancer patients who underwent surgical resection.
Cho HJ; Yun HJ; Yang HC; Kim SJ; Kang SK; Che C; Lee SD; Kang MW
J Surg Res; 2018 Jun; 226():40-47. PubMed ID: 29661287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
